Eli Lilly and Company (NYSE:LLY) Stock Has Average Target Price of $1,304.86

Eli Lilly and Company (NYSE:LLY) has been given a consensus rating of “Moderate Buy” by the thirty analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $1,308.39.

Several research firms recently commented on LLY. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. Sanford C. Bernstein raised their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. Finally, Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 23rd.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in LLY. BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. State Street Corp grew its holdings in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Capital World Investors increased its stake in Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after buying an additional 61,851 shares during the period. Bank of America Corp DE acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. Finally, Norges Bank acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $12,976,634,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves once-weekly insulin: The FDA authorized Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes. The treatment could reduce injections by more than 300 annually compared with daily basal insulin, broadening Lilly’s diabetes franchise and creating a new commercial opportunity. US FDA approves Lilly’s once-weekly insulin injection for type 2 diabetes
• Positive Sentiment: Strong obesity-drug momentum: Lilly says it is capturing approximately 70% of new seniors entering the Medicare GLP-1 program, while its oral obesity drug Foundayo is taking roughly one-third of new oral GLP-1 patients. This suggests Lilly is gaining share from Novo Nordisk as the obesity market expands. Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors
• Positive Sentiment: Pipeline and manufacturing investments: Lilly signed a research and licensing agreement with China’s InnoCare worth up to $3.35 billion, including $100 million upfront, and broke ground on a $6.5 billion Houston facility intended to support future obesity-drug production. These moves strengthen long-term pipeline diversification and supply capacity, although returns will depend on successful drug development and commercialization. China’s InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
• Neutral Sentiment: Competition and valuation remain important risks: Novo is pursuing new obesity products to regain market share, while Viking and other drugmakers are developing less-frequent dosing options. Lilly’s premium valuation also leaves less room for execution setbacks.

Eli Lilly and Company Price Performance

LLY stock opened at $1,183.22 on Friday. The stock has a market cap of $1.11 trillion, a PE ratio of 39.71, a P/E/G ratio of 1.44 and a beta of 0.50. Eli Lilly and Company has a 12 month low of $712.05 and a 12 month high of $1,292.65. The company has a 50-day moving average price of $1,176.99 and a 200 day moving average price of $1,082.06. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 36.54 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.